Literature DB >> 30056426

Decreased Parietal Beta Power as a Sign of Disease Progression in Patients with Mild Cognitive Impairment.

Christian Sandøe Musaeus1, Malene Schjønning Nielsen2, Natascha Nellum Østerbye2, Peter Høgh2,3.   

Abstract

BACKGROUND: Electroencephalography (EEG) power has previously been used to compare mild cognitive impairment (MCI) patients who progress to Alzheimer's disease (pMCI) with patients with MCI who remain stable (sMCI) by using beta power. However, the beta band is very broad and smaller frequency bands may improve accuracy.
OBJECTIVE: In the present study, we wanted to investigate whether it was possible to find any differences between pMCI and sMCI using relative power and whether these differences were correlated to cognitive function or neuropathology markers.
METHODS: 17 patients with AD, 27 patients with MCI, and 38 older healthy controls were recruited from two memory clinics and followed for three years. EEGs were recorded at baseline for all participants and relative power was calculated. All participants underwent adjusted batteries of standardized cognitive tests and lumbar puncture.
RESULTS: We found that pMCI showed decreased baseline relative power in the parietal electrodes in the beta1 band (13-17.99 Hz). At 2-year follow-up, we found changes in all baseline beta bands but most pronounced in the beta1 band. In addition, we found that qEEG parietal power was correlated with amyloid-β42 and anterograde memory.
CONCLUSION: These findings suggests that relative power in the parietal electrodes in the beta1 band may be a better way to discriminate between pMCI and sMCI at the time of diagnosis than the broad beta band. Similar findings have also been found with resting state fMRI. In addition, we found that anterograde memory was correlated to qEEG parietal beta1 power.

Entities:  

Keywords:  Alzheimer’s disease; EEG; mild cognitive impairment; progression

Mesh:

Substances:

Year:  2018        PMID: 30056426     DOI: 10.3233/JAD-180384

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Differences between memory encoding and retrieval failure in mild cognitive impairment: results from quantitative electroencephalography and magnetic resonance volumetry.

Authors:  Su-Hyun Han; Jung-Min Pyun; Soeun Yeo; Dong Won Kang; Ho Tae Jeong; Seung Wan Kang; SangYun Kim; Young Chul Youn
Journal:  Alzheimers Res Ther       Date:  2021-01-04       Impact factor: 6.982

2.  Olfactory response as a marker for Alzheimer's disease: Evidence from perceptual and frontal lobe oscillation coherence deficit.

Authors:  Mohammad Javad Sedghizadeh; Hadi Hojjati; Kiana Ezzatdoost; Hamid Aghajan; Zahra Vahabi; Heliya Tarighatnia
Journal:  PLoS One       Date:  2020-12-15       Impact factor: 3.240

3.  Resting state electroencephalographic rhythms are affected by immediately preceding memory demands in cognitively unimpaired elderly and patients with mild cognitive impairment.

Authors:  Alba Fernández; Giuseppe Noce; Claudio Del Percio; Diego Pinal; Fernando Díaz; Cristina Lojo-Seoane; Montserrat Zurrón; Claudio Babiloni
Journal:  Front Aging Neurosci       Date:  2022-08-05       Impact factor: 5.702

4.  Feasibility of Repeated Assessment of Cognitive Function in Older Adults Using a Wireless, Mobile, Dry-EEG Headset and Tablet-Based Games.

Authors:  Esther C McWilliams; Florentine M Barbey; John F Dyer; Md Nurul Islam; Bernadette McGuinness; Brian Murphy; Hugh Nolan; Peter Passmore; Laura M Rueda-Delgado; Alison R Buick
Journal:  Front Psychiatry       Date:  2021-06-25       Impact factor: 4.157

5.  Changes in the left temporal microstate are a sign of cognitive decline in patients with Alzheimer's disease.

Authors:  Christian S Musaeus; Knut Engedal; Peter Høgh; Vesna Jelic; Arjun R Khanna; Troels Wesenberg Kjaer; Morten Mørup; Mala Naik; Anne-Rita Oeksengaard; Emiliano Santarnecchi; Jon Snaedal; Lars-Olof Wahlund; Gunhild Waldemar; Birgitte B Andersen
Journal:  Brain Behav       Date:  2020-04-27       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.